ABSTRACT To determine the influence of adjunctive treatment with coumadin or aspirin on recurrence rate after percutaneous transluminal coronary angioplasty (PTCA), 248 patients in whom PTCA was assessed to be a primary success were randomized to either 325 mm aspirin daily or to coumadin treatment sufficient to maintain a prothrombin time 2 to 2.5 times the control value. The follow-up protocol included stress testing and coronary angiographic examinations 3 to 6 months after PTCA. All patients were followed for at least 9 months. Of the 122 patients randomized to coumadin 44 AFTER REVASCULARIZATION PROCEDURES such as coronary artery bypass grafting and coronary angioplasty there is often recurrence of stenosis. Several adjunctive therapies have been recommended to prevent thrombus formation with closure of graft or vessel. Early investigators in angioplasty recommended the use of coumadin as long-term adjunctive therapy after femoropopliteal transluminal angioplasty with the Dotter technique.' Thereafter, coumadin therapy was also used for peripheral dilatation with the balloon technique2 and later applied in coronary angioplasty.3 Long-term patency of 75% was achieved in European patients with adjunctive coumadin therapy after percutaneous transluminal coronary angioplasty (PTCA). The use of coumadin therapy was also supported by selected studies of the effectiveness of anticoagulants in patients after myocardial infarction.5 6 Other studies demonstrated benefit from the administration of aspirin after infarction.7-9 Schneider et al.10 reported the results of a randomized study comparing aspirin and
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Methods
Patients. Between December 15, 1980 and September 15, 1981, 299 patients underwent PTCA; 248 of the procedures were primary successes and the patients could be randomly assigned to receive aspirin or coumadin therapy for 6 months after dilatation. Angioplasty was performed via the femoral route by techniques described elsewhere.3 All patients were followed for at least 9 months after PTCA.
Criteria for inclusion in study. A Compliance with medication. Questionnaires designed to assess the degree of patient compliance with medication were sent to referring physicians. These data were reported in the form of a subjective assessment by the physician of the degree of compliance by the patient, which was described as excellent, good, fair, poor, or no compliance. In addition, prothrombin time values were requested from those patients maintained on coumadin and were reported as a comparison with control plasma values. Results reported as percent prothrombin activity were also accepted. For purposes of analysis, adequate coagulation was defined as B>1.9 times the control prothrombin time value or <20% prothrombin activity.
Statistics. The data were analyzed by means of a 'y analysis or by an unpaired Student t test in the case of comparison of means. Probabilities were taken from standard distribution tables and considered statistically significant at the .05 level. A discriminate analysis was performed on the data along with cross-table analysis to determine the predictive potential of selected variables on the outcome.
Results
Data from the 248 patients who were placed on adjunctive therapy were analyzed by the principle of intention to treat. The two groups that resulted from the randomization process were comparable with respect to epidemiologic factors such as age, sex, and the vessel that was dilated. The extent of disease as well as the response to dilatation as measured by pressure gradients and percent diameter of stenosis before and after dilatation were also similar (table 1) .
Follow-up data. Objective follow-up information was obtained in 92% (228/248) of all patients, and the amount of follow-up information obtained for the two subgroups did not differ significantly. Of the patients followed for a minimum of 9 months (range 9 to 18). The higher percentage of control angiograms obtained for the coumadin group was related to a higher recurrence rate in that group. When those patients with recurrences documented by angiography were eliminated, the number of patients with negative control angiograms in the coumadin and aspirin subgroups was similar. It should be noted that in only one case was it necessary to define recurrence on the basis of the results of an exercise stress test alone without coronary angiography.
Recurrence rate. The recurrence rate in the sample as a whole after 9 months of follow-up was 31.0% (78/ 248). Of these patients, 51/78 (65%) were available for a second dilatation procedure, with 45/51 (88%) having a favorable outcome. Detailed analysis of data from patients undergoing a second dilatation is not relevant to this study and therefore will not be further discussed. The coumadin subgroup had a recurrence rate after 9 months of 36.1% (44/122) as compared with a 27.0% (34/126) rate in the group on aspirin therapy (X' = 2.37, NS).
Duration of anginal symptoms. The mean duration of angina before PTCA was 6.94 ± 9.78 months in patients on coumadin therapy as opposed to 7.73 ± 11.77 months in patients on aspirin (mean ± SD). Spurious results in five patients who did not exclusively belong to either therapy group and who had a longer than 72 month history of angina were eliminated from the analysis.
In the entire sample of 248 patients, the duration of anginal symptoms in the months before PTCA made no significant difference in the determination of recurrence rate. On more detailed analysis, when duration of angina categories were broken down by therapy group, in all subgroups in which members had at least a 3 month history of angina the recurrence rate indicated that aspirin therapy was superior. In the subgroup with a 3 to 5 month history of angina this result reached statistical significance at the .05 level (table 2) .
When patients with a history of angina of 6 or more months were considered separately, the difference in recurrence rates between patients on coumadin and those on aspirin was statistically significant. The subgroup of coumadin patients with a longer duration of angina had a 44% recurrence rate ( 19/43) as opposed to a 21% rate (10/48) in patients on aspirin with a similar history (X2 = 5.70, p < .05). In patients with less than a 6 month history of symptoms the difference in recurrence rate between coumadin and aspirin subgroups was not statistically significant, with 32% (25/79) of coumadin patients and 31% (24/78) of aspirin patients having recurrent stenosis.
Compliance. Compliance data were provided for 85% (210/248) of patients in the study. The number of respondents with excellent or good compliance was greater in the aspirin than in the coumadin group as a whole, but the difference was not significant. A significant difference between the two groups was identified in that the percentage of coumadin patients on no therapy was higher than the percentage on no therapy in the aspirin group. Twenty-six percent (28/108) of patients on coumadin supplying information were not compliant with therapy as opposed to 15% (15/102) of aspirin patients (p < .05). However, the recurrence rate in these subgroups was not statistically significantly different (table 3) . Prothrombin time values were received for 63% (77/122) of patients on coumadin, of which 35% (27/77) were assessed as adequate. Twelve of these 27 patients (44%) had a recurrence.
Further analysis of compliance data revealed that when subgroups divided by degree of compliance with therapy were analyzed separately, no subgroup randomized to coumadin was found to have a recurrence (8/36) on aspirin (p < . 10). These findings point to an advantage of aspirin therapy over coumadin in the prevention of recurrence after PTCA in patients with at least a 6 month history of angina pectoris independent of differences in compliance (table 4). In the group of patients with a history of angina of less than 6 months, the recurrence rate was very similar between coumadin and aspirin subgroups (table 5 ). An additional point regarding compliance with medication is raised by the finding that upon analysis of data from those patients in the entire sample reporting no compliance with medication, the recurrence rate was found to be 28% (12/43). Admittedly these patients may be less symptomatic and thus less willing to take medication, but the result indicates that a randomized study of PTCA patients could include a group receiving placebo (table 6) .
Sample size. At the inception of the study a recurrence rate for coumadin in the range of 25% was predicted in accordance with previous European experi- ence.4 Since we believed that aspirin would prove to be the inferior of the two adjunctive therapies, a 35% recurrence rate with aspirin was taken to represent a clinically significant difference. Thus, it was determined that a sample size of 348 patients in each group or over 600 patients would be needed to demonstrate a statistically significant difference with a study power of 80% at the 5% probability level. On initial examination of the data in September 1981, however, it was found that coumadin therapy was associated with a higher percentage of patients with recurrent stenoses than was aspirin. This finding resulted in the termination of this study on clinical grounds. The sample size was thus limited to 248 patients. In addition, the 95% confidence interval for the difference between the two mean recurrence rates of 36% for coumadin and 27% for aspirin patients was [(-.03) Discussion This report represents the first known randomized study of patients undergoing PTCA. Although it was our hypothesis that coumadin would be proven more effective as adjunctive therapy after PTCA than aspirin, the results strongly indicate that the probability of coumadin therapy being associated with a reduced recurrence rate as compared with aspirin is very small. On the contrary, aspirin therapy was shown to be associated with a statistically significant advantage as compared with coumadin in prevention of recurrence of stenosis in patients with at least a 6 month history of anginal symptoms. This result was not related to a difference in patient compliance. It is important to note that at the time this study was undertaken, randomization of patients to placebo therapy would not have been considered clinically feasible. However, given the results of this study as well as accumulated clinical information, inclusion of a placebo group may be considered in future trials.
Since the possibility of emergency bypass surgery always exists with this procedure, coumadin therapy could not be started before PTCA. Thus, those patients randomized to coumadin were placed on this therapy immediately after the procedure. Since a gap of 2 to 3 days exists between the initial administration of coumadin and the attainment of therapeutic levels, this group was at a potential disadvantage because the effect of immediate post-PTCA adjunctive therapy on late outcome is unknown. Thus, both groups were maintained on equal aspirin dosages before and immediately after the procedure until coumadin levels became therapeutic.
The study was intended to evaluate adjunctive therapy as used in this country after coronary angioplasty. The responsibility was left in the hands of the referring physician to ensure patient compliance as previously described. There is admittedly a lack of control of blood levels of coumadin or aspirin, but it was thought that the creation of an artificially controlled situation of patient monitoring would not be representative of actual practice.
The importance of this study lies not in its demonstration of any advantage of adjunctive therapy with aspirin after PTCA, but rather with the finding that coumadin therapy appears no more efficacious than aspirin therapy after angioplasty. In summary, an analysis of data from a history of anginal symptoms of at least 6 months suggests that adjunctive therapy with aspirin is of significant value as compared with coumadin therapy in patients with a longer duration of anginal symptoms. Coumadin does not appear to be any more advantageous than aspirin in the prevention of recurrence of stenoses in patients after PTCA. Since there are numerous side effects of coumadin therapy, it should not be considered to be the preferred therapy after PTCA.
